Physician profile
Sunil H Patel
NPI 1134274012
$508,521.50
in general payments reported to CMS, 2019-2025
46 companies · $146K in 2025
The $146K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $7,620 · 2021: $14K · 2022: $67K · 2023: $114K · 2024: $140K · 2025: $146K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $201K · Travel and Lodging: $95K · Honoraria: $58K · Consulting Fee: $30K · Food and Beverage: $15K · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200,842.00 |
| Travel and Lodging | $95,484.99 |
| Honoraria | $57,940.00 |
| Consulting Fee | $30,467.50 |
| Food and Beverage | $14,973.66 |
| Education | $145.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $191,346.42 | 2019-2025 | Krystexxa, Uplizna, Repatha |
| Horizon Therapeutics Plc | $93,086.17 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $89,576.48 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $46,693.60 | 2019-2025 | Benlysta, Jesduvroq, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $35,271.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $30,861.21 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $6,707.04 | 2022-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $6,100.00 | 2024 | |
| Vifor Pharma, INC. | $1,850.03 | 2019-2023 | Korsuva, Veltassa |
| Abbott Laboratories | $836.76 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $751.71 | 2019-2025 | Verquvo, Zerbaxa, Dificid |
| Opko Pharmaceuticals, LLC | $659.42 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $621.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $488.19 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $483.53 | 2022-2025 | Jardiance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.